Francois Brisebois
Stock Analyst at Oppenheimer
(2.27)
# 2,715
Out of 5,147 analysts
74
Total ratings
39.19%
Success rate
0.65%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $95 → $105 | $75.52 | +39.04% | 8 | Feb 25, 2026 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $4.00 | +100.00% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $6.02 | -0.33% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $30.50 | +162.30% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $5.12 | +212.50% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.63 | +145.40% | 1 | Jan 29, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $28.54 | +113.74% | 6 | Jan 13, 2025 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $11.93 | +134.70% | 2 | Nov 6, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $336.75 | -51.60% | 4 | Oct 31, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $15.62 | +252.11% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.38 | +3,847.37% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $7.95 | -24.53% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.56 | +141.23% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $26.86 | -47.88% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $12.23 | +431.48% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.46 | +83.15% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $17.30 | +108.09% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $2,500 → $1,500 | $2.17 | +69,024.42% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.15 | +469,465.22% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $2.29 | +380.35% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $3.40 | +429.41% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $6.90 | +624.64% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $0.61 | +529,744.64% | 1 | Feb 4, 2020 |
Tarsus Pharmaceuticals
Feb 25, 2026
Maintains: Outperform
Price Target: $95 → $105
Current: $75.52
Upside: +39.04%
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $4.00
Upside: +100.00%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $6.02
Upside: -0.33%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $30.50
Upside: +162.30%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $5.12
Upside: +212.50%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.63
Upside: +145.40%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $28.54
Upside: +113.74%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $11.93
Upside: +134.70%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $336.75
Upside: -51.60%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $15.62
Upside: +252.11%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.38
Upside: +3,847.37%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $7.95
Upside: -24.53%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.56
Upside: +141.23%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $26.86
Upside: -47.88%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $12.23
Upside: +431.48%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.46
Upside: +83.15%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $17.30
Upside: +108.09%
Apr 3, 2023
Maintains: Outperform
Price Target: $2,500 → $1,500
Current: $2.17
Upside: +69,024.42%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.15
Upside: +469,465.22%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $2.29
Upside: +380.35%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $3.40
Upside: +429.41%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $6.90
Upside: +624.64%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $0.61
Upside: +529,744.64%